Targeting STAT3 inhibition to reverse Cisplatin (cas 15603-27-1) resistance

Add time:08/31/2019    Source:sciencedirect.com

Cisplatin (cas 15603-27-1) is one of the most frequently used chemotherapeutic agents for treatment of a wide range of cancer types. Nevertheless, the intrinsic or acquired resistance to cisplatin remains a major obstacle for cancer therapy. There are a number of factors contributing to the onset of this phenotype resistance. Signal transducers and activators of transcription 3 (STAT3) is constitutively activated in many cancer types, and such hyperactivation is associated with a poor clinical prognosis. In addition, STAT3 inhibitors have shown the ability to enhance the anti-tumor efficacy of cisplatin. In this review, we summarized the current knowledge of the STAT3 pathway in cancer treatment and its contribution to cisplatin resistance. Moreover, this review focuses on targeting STAT3 inhibition to overcome cisplatin resistance.

We also recommend Trading Suppliers and Manufacturers of Cisplatin (cas 15603-27-1). Pls Click Website Link as below: cas 15603-27-1 suppliers

Prev:Magnesium sulphate-silicone foam composites for thermochemical energy storage: Assessment of dehydration behaviour and mechanical stability
Next:Novel α,β-unsaturated hydroxamic acid derivatives overcome Cisplatin (cas 15603-27-1) resistance)